Menu
GWAS Study

A PRPH splice-donor variant associates with reduced sural nerve amplitude and risk of peripheral neuropathy.

Bjornsdottir G, Ivarsdottir EV, Bjarnadottir K et al.

30992453 PubMed ID
GWAS Study Type
6879 Participants
3 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

BG
Bjornsdottir G
IE
Ivarsdottir EV
BK
Bjarnadottir K
BS
Benonisdottir S
GS
Gylfadottir SS
AG
Arnadottir GA
BR
Benediktsson R
HG
Halldorsson GH
HA
Helgadottir A
JA
Jonasdottir A
JA
Jonasdottir A
JI
Jonsdottir I
KA
Kristinsdottir AM
MO
Magnusson OT
MG
Masson G
MP
Melsted P
RT
Rafnar T
SA
Sigurdsson A
SG
Sigurdsson G
SA
Skuladottir A
SV
Steinthorsdottir V
SU
Styrkarsdottir U
TG
Thorgeirsson G
TG
Thorleifsson G
VA
Vikingsson A
GD
Gudbjartsson DF
HH
Holm H
SH
Stefansson H
TU
Thorsteinsdottir U
NG
Norddahl GL
SP
Sulem P
TT
Thorgeirsson TE
SK
Stefansson K
Chapter II

Abstract

Summary of the research findings

Nerve conduction (NC) studies generate measures of peripheral nerve function that can reveal underlying pathology due to axonal loss, demyelination or both. We perform a genome-wide association study of sural NC amplitude and velocity in 7045 Icelanders and find a low-frequency splice-donor variant in PRPH (c.996+1G>A; MAF = 1.32%) associating with decreased NC amplitude but not velocity. PRPH encodes peripherin, an intermediate filament (IF) protein involved in cytoskeletal development and maintenance of neurons. Through RNA and protein studies, we show that the variant leads to loss-of-function (LoF), as when over-expressed in a cell line devoid of other IFs, it does not allow formation of the normal filamentous structure of peripherin, yielding instead punctate protein inclusions. Recall of carriers for neurological assessment confirms that from an early age, homozygotes have significantly lower sural NC amplitude than non-carriers and are at risk of a mild, early-onset, sensory-negative, axonal polyneuropathy.

6,879 Icelandic ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

6879
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Iceland
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.